DOCSLIB.ORG

NG198 Evidence Review F1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NG198 Evidence Review F1 FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Research recommendations for review question: For people with moderate to severe acne vulgaris what are the most effective treatment options? Research question - reduced dose oral isotretinoin What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why this is important Oral isotretinoin is prescribed by consultant dermatologist-led team for severe forms of acne resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy. The daily dose typically ranges between 0.5mg to 1mg/kg, however dosage adjustments may be required for people with severe intolerances or whom are at higher risk of developing serious adverse effects. There is limited high-quality data on the efficacy and optimum treatment duration of reduced (less than 0.5mg/kg) daily dose isotretinoin in acne. Furthermore, there have been reports of the successful use of reduced daily dose isotretinoin, including weekly (mini) or bi-weekly (micro) dosage regime as maintenance therapy in people with recurrent relapse despite adequate response to multiple courses of isotretinoin. The evidence for reduced dose isotretinoin as maintenance therapy have been limited to case series and small cohort studies. Further research will help to establish if • reduced daily dose of oral isotretinoin is effective in the treatment of acne vulgaris • reduced dose isotretinoin regime is effective as maintenance therapy; and • the optimum duration of treatment. Table 26: Research recommendation rationale Research question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Why is this needed Importance to ‘patients’ or the The daily dose of isotretinoin prescribed usually ranges between population 0.5mg – 1mg/kg. For some people, the dosage adjustment to the maximum tolerated dose may reduce the risk of adverse effects, as the risk of certain adverse effects is dose dependent. However, there is limited high-quality data on the effectiveness of reduced daily dose of isotretinoin for treating acne and the optimum duration of treatment. In people with recurrent acne relapse despite adequate response to multiple courses of isotretinoin, reduced dose isotretinoin regime may be an attractive option. However, evidence for reduced dose isotretinoin in this population is limited to case series and small cohort studies. Relevance to NICE guidance There was limited evidence for the use of oral isotretinoin at a reduced daily dose in acne for the committee to make a strong recommendation. There was a lack of data on the use of low dose isotretinoin in acne maintenance therapy for any recommendations to be made. Therefore, research investigating the efficacy and safety of reduced dose oral isotretinoin is warranted. 394 Acne vulgaris: evidence reviews for management options for people with moderate to severe acne vulgaris (NMA) FINAL(June 2021) FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Research question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Relevance to the NHS Acne vulgaris, which is the eighth most prevalent disease globally, affects the majority of teenagers and young adults and is common in the UK. Severe intolerance, significant adverse effects are dose dependent and therefore reduced dose oral isotretinoin may offer a safer and effective alternative to standard dose oral isotretinoin. For people with recurrent relapsing acne, treatment options are currently limited and reduced daily dose including mini and micro dose regimes may be a suitable and effective option as maintenance treatment. National priorities • The Medicines and Healthcare Products Regulatory Agency (MHRA) in 2020 are in the process of conducting an in-depth review of psychiatric and sexual adverse effects of oral isotretinoin with the aim to reduce risk of these adverse effects. As many isotretinoin associated adverse effects are dose related, there is a clear benefit of investigating whether reduced dose oral isotretinoin is safe and effective. • Reducing antibiotic prescribing in order to prevent antimicrobial resistance is a national priority. It would be helpful to determine whether reduced dose oral isotretinoin would be an effective and safe alternative to repeated courses of oral and/or topical antibiotics in the treatment of acne and as maintenance therapy. Current evidence base Limited research has been conducted on this area and therefore additional, high-quality studies are required. Equality Not applicable Feasibility People receiving oral isotretinoin would need to be provided with adequate detailed information about the potential adverse effects of isotretinoin and participants in studies investigating reduced dose oral isotretinoin would need to be monitored for these adverse effects. Other comments Not applicable Table 27: Research recommendation characteristics table Criterion Explanation Population People with: • severe forms of acne resistant to adequate courses of standard therapy with systemic antibacterials and topical therapy • refractory acne vulgaris despite previous treatment courses with standard daily dose oral isotretinoin • cleared acne who require maintenance treatment due to previous relapses. Intervention Reduced dose oral isotretinoin as: • reduced daily dose (less than 0.5mg/kg) • reduced dose regime (mini or micro) Comparator • Standard daily dose of isotretinoin • Treatment that includes an oral antibiotic 394 Acne vulgaris: evidence reviews for management options for people with moderate to severe acne vulgaris (NMA) FINAL(June 2021) FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Criterion Explanation Outcomes • Clinician reported improvement, including change in acne lesion count • Patient reported improvement • Recurrence • Adverse events, in particular: - mucosal / cutaneous changes (for example new chelitis) - change in mood - new psychiatric diagnosis - suicidality Study design Randomised controlled trial Timeframe • 6 months (intervention) and 12 months (follow-up) for treatment study • 12 months (intervention) and 12 months (follow-up) for maintenance study Additional information Not applicable Research question - physical modalities (excluding chemical peels) What is the effectiveness of physical modalities, (such as light devices) in the treatment of acne vulgaris orpersistent acne vulgaris-related scarring? Why this is important Physical treatments for acne are popular with people because they have the benefit of treating a local area without systemic effects. They can be used in people with co-morbidities or side effects where other treatments are unsuitable. They are currently available in the private sector but there is no standardisation of treatment modalities or duration. Many different physical therapies have been described for acne including: • Comedone extraction • Phototherapy – including UVB, intense pulsed light, blue and red light • Photochemical therapy (e.g. photodynamic therapy) • Laser • Photopneumatic therapy (e.g. intense pulsed light + vacuum) • Photothermal therapy (eg gold nanoparticles +light or laser) Physical treatments are also used for acne scarring. These include: • Punch excision • CO2 laser • Dermabrasion • Radiofrequency (e.g. fractional microneedling, bipolar) Further research is required to determine the most effective physical treatments for acne and acne scarring. This could open the way to wider availability in the NHS. Table 28: Research recommendation rationale Research question What is the effectiveness of physical modalities (such as light devices) in the treatment of acne vulgaris or persistent acne vulgaris-related scarring? Why is this needed 394 Acne vulgaris: evidence reviews for management options for people with moderate to severe acne vulgaris (NMA) FINAL(June 2021) FINAL Management options for people with moderate to severe acne vulgaris - network meta-analyses Research question What is the effectiveness of physical modalities (such as light devices) in the treatment of acne vulgaris or persistent acne vulgaris-related scarring? Importance to ‘patients’ or the Physical treatments for acne are popular with people because population they have the benefit of treating a local area without systemic effects. They can be used in people with co-morbidities or side effects where other treatments are unsuitable. There is evidence from small studies that physical therapies including various light sources with or without addition of chemical or physical photosensitiser may be effective in all grades of acne. There is also some evidence to support CO2 laser treatment for acne scarring. However, the studies are too small or of insufficient quality to allow recommendations to be made. Relevance to NICE guidance Currently physical treatments for acne vulgaris cannot be recommended. Weak recommendation can be made for CO2 laser for acne scarring, but stronger evidence is required to allow a stronger recommendation. which would lead to wider availability on NHS. Relevance to the NHS Acne vulgaris is the most common skin condition affecting the majority of teenagers and young adults. Acne scarring leads to lifelong psychological distress for some people. Physical treatments for acne could provide an alternative for people unwilling or unable to use other treatment modalities. With more
Load more

Recommended publications
  • NG198 Evidence Review E1
    1 2 Research recommendations for review question: For people with mild to 3 moderate acne vulgaris what are the most effective treatment options? 4 Research question - physical modalities 5 What is the effectiveness of physical modalities (such as light devices) in the treatment of 6 acne vulgaris or persistent acne vulgaris-related scarring? 7 Why this is important 8 Physical treatments for acne are popular with people because they have the benefit of 9 treating a local area without systemic effects. They can be used in people with co-morbidities 10 or side effects where other treatments are unsuitable. They are currently available in the 11 private sector but there is no standardisation of treatment modalities or duration. Many 12 different physical therapies have been described for acne including: 13 • Comedone extraction 14 • Phototherapy – including UVB, intense pulsed light, blue and red light 15 • Photochemical therapy (e.g. photodynamic therapy) 16 • Laser 17 • Photopneumatic therapy (e.g. intense pulsed light + vacuum) 18 • Photothermal therapy (eg gold nanoparticles +light or laser) 19 Physical treatments are also used for acne scarring. These include: 20 • Punch excision 21 • CO2 laser 22 • Dermabrasion 23 • Radiofrequency (e.g. fractional microneedling, bipolar) 24 Further research is required to determine the most effective physical treatments for acne and 25 acne scarring. This could open the way to wider availability in the NHS. 26 Table 26: Research recommendation rationale Research question What is the effectiveness of physical modalities (such as light devices) in the treatment of acne vulgaris or persistent acne vulgaris-related scarring? Why is this needed Importance to ‘patients’ or the Physical treatments for acne are popular with people because population they have the benefit of treating a local area without systemic effects.
    [Show full text]
  • June 2021 Therapeutic Research Center (TRC) Is the Leading Advisory Service on Drug Therapy and Medication Management
    June 2021 Therapeutic Research Center (TRC) is the leading advisory service on drug therapy and medication management. Every month over 400,000 prescribers, pharmacists, and pharmacy technicians rely on our unbiased, evidence-based clinical recommendations to help them improve medication use, prevent medication errors, and improve patient care and outcomes. We also have one of the most extensive CE/CME course offerings in the industry. Our accredited continuing education and continuing medical education courses are trusted and relied on by hundreds of thousands of pharmacists, technicians, and prescribers every month. Therapeutic Research Center does not receive commercial support and does not accept any advertising. It is completely independent and is supported entirely by subscriptions. Credit is reported to CPE Monitor, AAFP, and CE Broker as appropriate. Accreditation Information: Therapeutic Research Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians. Pharmacist’s Letter / Therapeutic Research Center is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Therapeutic Research Center / Prescriber’s Letter is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number:080517. Select Therapeutic Research Center courses are also acceptable for American Academy of Family Physicians (AAFP) Prescribed credit, American Osteopathic Association (AOA) credit, and American College of Emergency Physicians (ACEP) Category I Credit. Please refer to the detailed accreditation statements available online for each course. Get started at TherapeuticResearchCenter.com. Log in to access your course list or purchase a course or subscription. For additional assistance, please call 209-472-2240 and we’ll be happy to help you.
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • Acne Vulgaris
    CLINICAL REVIEW What’s New in the Management of Acne Vulgaris Leon H. Kircik, MD A better understanding of acne pathophysiology and the PRACTICE POINTS role of inflammation has, however, yielded a better under- • Sarecycline is the first new antibiotic approved for standing of how existing therapies treat the disease and acne in several years. have led to more comprehensive treatment strategies that • Tazarotene foam 0.1% was relaunched to the market. are multitargeted. Nonetheless, topical and oral antibiotics The foam formulation attempts to impart moisturizing remain mainstays of acne therapy, along with topical reti- effects to offset potential irritation. noids and benzoyl peroxide. Current guidelines of care for • Topical minocycline for acne optimizes the therapeutic acne emphasize strategies that reduce dependence on anti- effects while reducing systemic effects. biotics and minimizecopy the risk for resistance.4 The therapeutic • Clascoterone and cannabidiol currently are under landscape might at last be shifting, with new chemical enti- investigation for acne treatment. ties for acne and several novel formulations in development. Sarecycline: A Novel Tetracycline Tetracyclinenot antibiotics have been used to manage acne Drug development continues to focus on the challenge of treat- since the 1950s, but their method of action in the disease ing acne effectively and safely. Inflammation is a backdrop to has not been fully elucidated.5 In addition to antibiotic the commonly cited elements of the pathophysiology of acne: effects, tetracyclines have been shown to confer anti- Propionibacterium acnes proliferation, increased sebum Dopro- inflammatory properties and other biologic effects.6,7 duction with an increase in circulating androgens, and faulty keratinization.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • 1 EMA Tender EMA/2017/09/PE, Lot 2 Impact of EU Label
    EMA tender EMA/2017/09/PE, Lot 2 Impact of EU label changes and revised pregnancy prevention programme for oral retinoid containing medicinal products: risk awareness and adherence Protocol • Prof. Anna Birna Almarsdóttir, Professor in Social and Clinical Pharmacy at the Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen • Prof. Marcel Bouvy, Professor of Pharmaceutical Care at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Rob Heerdink, Associate Professor at the Division of Pharmacoepidemiology & Clinical Pharmacology of the Department of Pharmaceutical Sciences, Utrecht University. • Dr Teresa Leonardo Alves, Researcher at the Centre for Health Protection, National Institute for Public Health and the Environment, The Netherlands. 1 Table of contents Background ...................................................................................................................... 3 Aims of the study ............................................................................................................. 4 Methods ........................................................................................................................... 4 Setting ........................................................................................... Error! Bookmark not defined. Study design ............................................................................................................................ 4 Population
    [Show full text]
  • Isotretinoin (Accutane) and Pregnancy
    Isotretinoin (Accutane®) This sheet talks about exposure to isotretinoin in a pregnancy or while breastfeeding. This information should not take the place of medical care and advice from your healthcare provider. What is isotretinoin? Isotretinoin is a prescription medication taken by mouth to treat severe cystic acne that has not responded to other treatments. Isotretinoin is a form of Vitamin A. It has been sold under brand names such as Accutane®, Absorica®, Amnesteem®, Claravis®, Epuris®, Clarus®, Myorisan®, Sotret®, and Zenatane®. How long after a woman stops taking isotretinoin should she wait to become pregnant? How long does isotretinoin stay in the body? It is recommended that a woman wait one month after stopping isotretinoin before trying to become pregnant. Usually, isotretinoin is no longer found in a woman’s blood 4-5 days after the last dose and most of its by-products should be gone within 10 days after the last dose. However, the time it takes isotretinoin to be cleared from the body can be longer in some people, which is why it is recommended to wait at least one month after stopping isotretinoin before trying to become pregnant. Can isotretinoin make it more difficult to get pregnant? Women who are trying to become pregnant should not be taking isotretinoin. There have been reports of irregular menstrual periods in some women taking isotretinoin. There are no reports of problems getting pregnant while taking isotretinoin. I just found out I am pregnant. Should I stop taking isotretinoin? Stop taking the medication right away. As soon as possible, call the healthcare provider who prescribed the isotretinoin and the healthcare provider who will be taking care of you during your pregnancy.
    [Show full text]
  • Isotretinoin for Neuroblastoma
    Isotretinoin for Neuroblastoma Isotretinoin (EYE so TRET in oin) is a form of vitamin A that is very concentrated. It can only be obtained by prescription. The oily liquid comes in a soft capsule. Brand names for this medicine are Amnesteem®, Absorica®, Claravis®, Myorisan® and Zenatane®. Isotretinoin is used to treat neuroblastoma, the most common type of cancer in children. This medicine is given along with other immunotherapy (cancer fighting) drugs during the active stage of illness. It may also be ordered to be taken during the maintenance phase of therapy. Usually isotretinoin is given after the child has received the medicine 131I- Metaiodobenzylguanidine (MIBG) and has had a Bone Marrow Transplant (BMT). Warnings If your child is allergic to retinoids, he should not take this medicine. When handling this drug, extreme care needs to be followed by women who are pregnant or breastfeeding. Isotretinoin can cause severe birth defects and can pass into breast milk. Someone else will need to give this medicine to your child. Because of the dangers of birth defects with isotretinoin, your child, your child’s doctor, and your pharmacy must register with the iPLEDGE™ program. To do this, go to www.ipledgeprogram.com. Failure to register means that your child will not get the medicine. When your child needs more medicine, the doctor will have to write a new prescription each time. How to give Isotretinoin can be given by mouth whole, buried in food whole, or dissolved and mixed with food. Always wear disposable gloves if there is a risk of touching the liquid inside the capsule.
    [Show full text]
  • Acitretin; Adapalene; Alitretinoin; Bexarotene; Isotretinoin
    8 February 2018 EMA/254364/2018 Pharmacovigilance Risk Assessment Committee (PRAC) Assessment report Referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data Retinoids containing medicinal products INN: Acitretin, Adapalene, Alitretinoin, Bexarotene, Isotretinoin, Tretinoin, Tazarotene Procedure number: EMEA/H/A-31/1446 Panretin EMEA/H/A-31/1446/C/000279/0037 Targretin EMEA/H/A-31/1446/C/000326/0043 Note: Assessment report as adopted by the PRAC and considered by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ......................................................................................... 2 1. Information on the procedure ................................................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Introduction......................................................................................................... 3 2.2. Clinical aspects .................................................................................................... 5 2.3. Data on efficacy ..................................................................................................
    [Show full text]
  • Aetna Formulary Exclusions Drug List
    Covered and non-covered drugs Drugs not covered – and their covered alternatives 2020 Advanced Control Plan – Aetna Formulary Exclusions Drug List 05.03.525.1B (7/20) Below is a list of medications that will not be covered without a Key prior authorization for medical necessity. If you continue using one of these drugs without prior approval, you may be required UPPERCASE Brand-name medicine to pay the full cost. Ask your doctor to choose one of the generic lowercase italics Generic medicine or brand formulary options listed below. Preferred Options For Excluded Medications1 Excluded drug name(s) Preferred option(s) ABILIFY aripiprazole, clozapine, olanzapine, quetiapine, quetiapine ext-rel, risperidone, ziprasidone, VRAYLAR ABSORICA isotretinoin ACANYA adapalene, benzoyl peroxide, clindamycin gel (except NDC^ 68682046275), clindamycin solution, clindamycin-benzoyl peroxide, erythromycin solution, erythromycin-benzoyl peroxide, tretinoin, EPIDUO, ONEXTON, TAZORAC ACIPHEX, esomeprazole, lansoprazole, omeprazole, pantoprazole, DEXILANT ACIPHEX SPRINKLE ACTICLATE doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg [NDC^ 72143021160 only], 75 mg, 150 mg), minocycline, tetracycline ACTOS pioglitazone ACUVAIL bromfenac, diclofenac, ketorolac, PROLENSA acyclovir cream acyclovir (except acyclovir cream), valacyclovir ADCIRCA sildenafil, tadalafil ADZENYS XR-ODT amphetamine-dextroamphetamine mixed salts ext-rel†, dexmethylphenidate ext-rel, dextroamphetamine ext-rel, methylphenidate ext-rel†, MYDAYIS,
    [Show full text]
  • Acitretin; Adapalene; Alitretinoin; Bexarotene; Isotretinoin
    21 June 2018 EMA/261767/2018 Updated measures for pregnancy prevention during retinoid use Warning on possible risk of neuropsychiatric disorders also to be included for oral retinoids On 22 March 2018, the European Medicines Agency (EMA) completed its review of retinoid medicines, and confirmed that an update of measures for pregnancy prevention is needed. In addition, a warning on the possibility that neuropsychiatric disorders (such as depression, anxiety and mood changes) may occur will be included in the prescribing information for oral retinoids (those taken by mouth). Retinoids include the active substances acitretin, adapalene, alitretinoin, bexarotene, isotretinoin, tazarotene and tretinoin. They are taken by mouth or applied as creams or gels to treat several conditions mainly affecting the skin, including severe acne and psoriasis. Some retinoids are also used to treat certain forms of cancer. The review confirmed that oral retinoids can harm the unborn child and must not be used during pregnancy. In addition, the oral retinoids acitretin, alitretinoin and isotretinoin, which are used to treat conditions mainly affecting the skin, must be used in accordance with the conditions of a new pregnancy prevention programme by women able to have children. Topical retinoids (those applied to the skin) must also not be used during pregnancy, and by women planning to have a baby. More information is available below. Regarding the risk of neuropsychiatric disorders, the limitations of the available data did not allow to clearly establish whether this risk was due to the use of retinoids. However, considering that patients with severe skin conditions may be more vulnerable to neuropsychiatric disorders due to the nature of the disease, the prescribing information for oral retinoids will be updated to include a warning about this possible risk.
    [Show full text]
  • Risk Assessment and Risk Mitigation Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213433Orig1s000 RISK ASSESSMENT and RISK MITIGATION REVIEW(S) Division of Risk Management (DRISK) Office of Medication Error Prevention and Risk Management (OMEPRM) Office of Surveillance and Epidemiology (OSE) Center for Drug Evaluation and Research (CDER) Application Type NDA Application Number 213433 PDUFA Goal Date August 27, 2020 OSE RCM # 2019-1748 Reviewer Name Yasmeen Abou-Sayed, PharmD Acting Team Leader Jacqueline Sheppard, PharmD Acting Deputy Division Doris Auth, PharmD Director Review Completion Date August 21, 2020 Subject Evaluation of Need for a REMS Established Name clascoterone Trade Name Winlevi Name of Applicant Cassiopea SpA Therapeutic Class Androgen receptor inhibitor Formulation 1% Topical cream Dosing Regimen Applied to the affected areas twice daily 1 Reference ID: 4660260 Table of Contents EXECUTIVE SUMMARY ......................................................................................................................................................... 3 1 Introduction ..................................................................................................................................................................... 3 2 Background ...................................................................................................................................................................... 3 2.1 Product Information ..........................................................................................................................................
    [Show full text]